Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Reports 9.2-Percent Increase in Q4 Revenues

NEW YORK, Feb. 9 (GenomeWeb News) - Sigma-Aldrich yesterday reported net sales of $352 million in the fourth quarter of 2004, up 9.2 percent from $322 million in the same period in 2003.

 

The increase was bolstered by a 4.8-percent currency gain, Sigma said, as well as contributions from Ultrafine and Tetrionics, which Sigma acquired in Q2 of 2004. Approximately one-half of Sigma's sales are in currencies other than dollars, and its revenues reflect benefits from exchange rates.

 

Revenues in Sigma's biotechnology unit spiked to $76.2 million in Q4 2004 from $72.6 million in Q4 2003.

 

Sigma recorded a gross profit of $187.4 million last quarter, up from $168.9 million in the year-ago period. Sigma's R&D expenses remained steady between Q4 2004 and 2003 at $11.1 million.

 

The St. Louis-based firm reported $169.2 million in cash and cash equivalents as of Dec. 31, 2004.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.